1. EEOICPA Compensation Results (through March 2004) Russ Henshaw, MS Epidemiologist NIOSH/Office of Compensation Analysis & Support Cincinnati, OH

2. Completed Claim Results: Important Caveats  Results are through March 31, 2004  Includes only those cases in which NIOSH has received notice from DOL of an official compensation decision (~ 2/3 of cases)  May NOT be predictive of future results  Unless otherwise noted, results are for claims with only one primary cancer

3. Completed Claims: Proportion That Were Compensable, by NIOSH-IREP Cancer Model Cancer Model (ICD-9 Code)Total Compensated Oral Cavity and Pharynx (140-149) 23 4 (17%) Esophagus (150)190 (0%) Stomach (151)210 (0%) Colon (153)781 (1%) Rectum (154)270 (0%)

4. Completed Claims: Proportion That Were Compensable, by NIOSH-IREP Cancer Model (Cont.) Cancer Model (ICD-9 Code)Total Compensated All digestive (150-159) 3 0 (0%) Liver (155.0)75 (71%) Gallbladder (155.1, 156)31 (33%) Pancreas (157)430 (0%) Lung (162)230209 (91%)

5. Completed Claims: Proportion That Were Compensable, by NIOSH-IREP Cancer Model (Cont.) Cancer Model (ICD-9 Code)Total Compensated Other respiratory (160, 161, 163-165) 19 6 (32%) Bone (170)31 (33%) Connective tissue (171)130 (0%) Malignant melanoma (172)193 (16%) Non-melanoma skin-Basal Cell (173)2511 (44%)

6. Completed Claims: Proportion That Were Compensable, by NIOSH-IREP Cancer Model (Cont.) Cancer Model (ICD-9 Code)Total Compensated Non-melanoma skin-Squamous Cell (173) 16 1 (6%) Breast (174-175)691 (1%) Ovary (183)20 (0%) Female genitalia, excluding ovary (179-182, 184) 140 (0%) All male genitalia (185-187)2190 (0%)

7. Completed Claims: Proportion That Were Compensable, by NIOSH-IREP Cancer Model (Cont.) Cancer Model (ICD-9 Code)Total Compensated Bladder (188) 42 2 (5%) Urinary organs, excluding bladder (189)115 (45%) Eye (190)20 (0%) Nervous system (191-192)330 (0%) Thyroid (193)140 (0%)

8. Completed Claims: Proportion That Were Compensable, by NIOSH-IREP Cancer Model (Cont.) Cancer Model (ICD-9 Code)Total Compensated Other endocrine glands (194) 2 0 (0%) Other and ill-defined sites (195)0N/A Lymphoma & multiple myeloma (200-203) 902 (2%) Leukemia, excluding CLL (204-208, excluding 204.1) 65 (83%) Acute Lymphocytic Leukemia (204.0) 3 3 (100%)

9. Completed Claims: Proportion That Were Compensable, by NIOSH-IREP Cancer Model (Cont.) Cancer Model (ICD-9 Code)Total Compensated Acute Myeloid Leukemia (205.0)83 (38%) Chronic Myeloid Leukemia (205.1)75 (71%) Claims with unknown primary cancer2824 (86%) Claims with multiple primary cancers226146 (65%) All Completed Claims1325438 (33%)

10. Compensability Rate, by Cancer Model (10 or More Completed Cases)

12.  0% (no compensable cases):  Esophagus  Stomach  Rectum  Pancreas  Connective tissue  Female genitalia, excluding ovary  All male genitalia  Nervous system  Thyroid

13. Compensability Rates for “Unknown Primary” and “Multiple Primary” Claims

14. Proportion of Claims That Were Compensable, by Years Worked

15. Proportion of Claims That Were Compensable, by Age at Diagnosis

16. Lung Cancer Compensability (Single Primary Cancer) by Smoking Status

18. Compensability Rate by Gender (All Completed Claims)

19. Summary  Some initial surprises, but current results are skewed:  By dose reconstruction “efficiency process”  Possibly by incomplete data (we are awaiting official decisions from DOL for about 1/3 of all completed cases)  Data will continue to be monitored for trends & anomalies  Results are not predictive of future claims